Research library
LL-37, explained
12 guides, organized by the question you are trying to answer.
Research Guides
Antimicrobial activity is not proof of infection treatment
How to distinguish LL-37 laboratory findings from evidence needed to replace or supplement clinical anti-infective care.
Can bacteria be less susceptible to LL-37? A surface-chemistry example
Why a host-defense origin does not establish resistance-proof activity against every bacterial strain.
LL-37 and biofilms: identify the model before the claim
A reader’s guide to attachment, biofilm biomass, bacterial growth and the limits of laboratory antibiofilm findings.
LL-37 and cancer: opposite findings can both require context
Separate ovarian and colon experimental models, human tissue associations and a tiny intratumoral trial record.
HCAP-18 and LL-37: why the precursor is not the finished peptide
Understand the original protein-processing research and why gene expression does not establish administered-peptide benefit.
LL-37 and innate immunity: activation is not automatically beneficial
Understand why LL-37’s immune signaling cannot be reduced to a general immune-boosting claim.
LL-37 in periodontal fluid: delivery depends on what happens locally
Read the gingival-fluid and saliva experiments without turning them into a periodontitis treatment claim.
LL-37 as an autoantigen: what the psoriasis T-cell study means
Understand antigen recognition without confusing it with allergy, an injection-risk estimate or an immune-health benefit.
Rosacea research shows why peptide processing matters
Separate human skin observations and mouse experiments from claims about using LL-37 for redness or skin repair.
LL-37 safety: route and formulation belong in the first question
Read FDA’s current safety entry without mistaking withdrawn nomination status or topical tolerability for approval.
LL-37 wound-healing trials: the larger study was negative overall
Read the small early topical trial alongside HEAL LL-37, including its full-cohort result and post hoc subgroup.
Vitamin D and cathelicidin: a pathway is not a supplement prescription
Read the human-cell mechanism studies without assuming vitamin D, endogenous LL-37 and injected peptide are interchangeable.
